Mobile Site ›

Print Page Email Page
Print Friendly View

Test ID: IGFP
Insulin-Like Growth Factor 1 (IGF-1) and Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Growth Panel

Useful For Suggests clinical disorders or settings where the test may be helpful

This is the preferred test for assessing growth hormone-related disorders (eg, growth disorders, including acromegaly and gigantism; adult growth hormone deficiency) and for monitoring recombinant growth hormone treatment.

 

Measurement of both insulin-like growth factor 1 and insulin-like growth factor binding protein 3 appears superior to determining either analyte alone, for all clinical applications.

 

See Individual Unit Codes.

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

See Individual Unit Codes

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

INSULIN-LIKE GROWTH FACTOR 1

 

Age

 

ng/mL

0.1 Percentile (ng/mL)

Males:

15 days-5 months

48-313

39

6-11 months

57-344

34

1 year

55-327

33

2 years

51-303

31

3 years

49-289

30

4 years

49-283

29

5 years

50-286

30

6 years

52-297

31

7 years

52-300

31

8 years

58-329

35

9 years

67-373

41

10 years

80-438

49

11 years

101-538

62

12 years

131-690

82

13 years

172-872

108

14 years

215-1,026

137

15 years

236-1,060

153

16 years

227-964

150

17 years

199-795

133

18 years

170-640

 

19 years

147-527

 

20 years

132-457

 

21-25 years

116-341

 

26-30 years

117-321

 

31-35 years

113-297

 

36-40 years

106-277

 

41-45 years

98-261

 

46-50 years

91-246

 

51-55 years

84-233

 

56-60 years

78-220

 

61-65 years

72-207

 

66-70 years

67-195

 

71-75 years

62-184

 

76-80 years

57-172

 

>80 years

53-162

 

Females:

 

 

15 days-5 months

48-313

39

6-11 months

57-344

34

1 year

55-327

33

2 years

51-303

31

3 years

49-289

30

4 years

49-283

29

5 years

50-286

30

6 years

52-297

31

7 years

62-316

39

8 years

70-344

44

9 years

81-389

52

10 years

97-453

62

11 years

122-551

79

12 years

155-680

101

13 years

190-805

125

14 years

222-896

148

15 years

238-917

161

16 years

228-839

157

17 years

194-680

135

18 years

162-541

 

19 years

138-442

 

20 years

122-384

 

21-25 years

116-341

 

26-30 years

117-321

 

31-35 years

113-297

 

36-40 years

106-277

 

41-45 years

98-261

 

46-50 years

91-246

 

51-55 years

84-233

 

56-60 years

78-220

 

61-65 years

72-207

 

66-70 years

67-195

 

71-75 years

62-184

 

76-80 years

57-172

 

>80 years

53-162

 

Reference values have not been established for patients that are less than 3 weeks of age.

 

INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3

1-7 days: < or =0.7 mcg/mL

8-14 days: 0.5-1.4 mcg/mL

15 days-11 months: unavailable

1 year: 0.7-3.6 mcg/mL

2 years: 0.8-3.9 mcg/mL

3 years: 0.9-4.3 mcg/mL

4 years: 1.0-4.7 mcg/mL

5 years: 1.1-5.2 mcg/mL

6 years: 1.3-5.6 mcg/mL

7 years: 1.4-6.1 mcg/mL

8 years: 1.6-6.5 mcg/mL

9 years: 1.8-7.1 mcg/mL

10 years: 2.1-7.7 mcg/mL

11 years: 2.4-8.4 mcg/mL

12 years: 2.7-8.9 mcg/mL

13 years: 3.1-9.5 mcg/mL

14 years: 3.3-10 mcg/mL

15 years: 3.5-10 mcg/mL

16 years: 3.4-9.5 mcg/mL

17 years: 3.2-8.7 mcg/mL

18 years: 3.1-7.9 mcg/mL

19 years: 2.9-7.3 mcg/mL

20 years: 2.9-7.2 mcg/mL

21-25 years: 3.4-7.8 mcg/mL

26-30 years: 3.5-7.6 mcg/mL

31-35 years: 3.5-7.0 mcg/mL

36-40 years: 3.4-6.7 mcg/mL

41-45 years: 3.3-6.6 mcg/mL

46-50 years: 3.3-6.7 mcg/mL

51-55 years: 3.4-6.8 mcg/mL

56-60 years: 3.4-6.9 mcg/mL

61-65 years: 3.2-6.6 mcg/mL

66-70 years: 3.0-6.2 mcg/mL

71-75 years: 2.8-5.7 mcg/mL

76-80 years: 2.5-5.1 mcg/mL

81-85 years: 2.2-4.5 mcg/mL

 

TANNER STAGES

Males

Stage I: 1.2-6.4 mcg/mL

Stage II: 2.8-6.9 mcg/mL

Stage III: 3.9-9.4 mcg/mL

Stage IV: 3.3-8.1 mcg/mL

Stage V: 2.7-9.1 mcg/mL

Females

Stage I: 1.4-5.2 mcg/mL

Stage II: 2.3-6.3 mcg/mL

Stage III: 3.1-8.9 mcg/mL

Stage IV: 3.7-8.7 mcg/mL

Stage V: 2.6-8.6 mcg/mL

Interpretation Provides information to assist in interpretation of the test results

See Individual Unit Codes

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

See Individual Unit Codes

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

See Individual Unit Codes